Abstract Purpose: To identify independent clinicopathologic factors and protein markers leading to the identification of colorectal cancer (CRC) patients with mismatch repair proficiency at risk of developing metastasis and, consequently, more likely to benefit from combined modality therapy. Experimental Design: Immunohistochemistry for 22 tumor markers was done using a tissue microarray. A subset of 387 CRC patients with complete clinicopathologic data and TNM stage was analyzed. Univariate and multivariate analyses were done to identify independent predictive markers of metastasis. The results were validated on 810 CRC patients.
The TNM classification remains the most reliable indicator of prognosis for patients with colorectal cancer (CRC) and provides the basis for therapeutic decision making (1) . Patients with stage III disease and therefore with lymph node involvement are usually treated with adjuvant radiotherapy/ chemotherapy whereas those without local metastatic spread typically undergo surgery (2) . The treatment of patients with stage II disease by adjuvant chemotherapy remains a matter of controversy. The MOSAIC B2 meta-analysis of stage II subgroups showed a nonsignificant benefit in disease-free and overall survival with fluorouracil and leucovorin (3) . On the other hand, the MOSAIC, QUASAR, and NSABP C-07 trials showed considerable improvements in survival in patients with node-negative disease (4 -6) . These results were supported by recent meta-analyses of fluorouracil-based adjuvant therapy for patients with stage II disease (7, 8) .
Although high-risk node negative patients may benefit from adjuvant therapy, these patients are primarily identified as those with T 4 lesions, perforation, poorly differentiated histology, and peritumoral lymphovascular involvement (9) . Molecular characterization of tumors may improve the identification of patients at high risk of developing metastasis following surgery, thereby resulting in individualized treatment planning and improved selection of patients for adjuvant therapy (1) .
Several tumor markers are currently being investigated for their prognostic or predictive value in CRC. Mutation of p53 is reported in f70% of CRCs and is correlated with advanced disease stage, lymph node metastasis, and increased risk of distant metastasis in the majority of studies (10 -17) . The epidermal growth factor receptor has been linked to tumor progression, increased risk of liver metastasis, vascular invasion, and worse survival (18 -22) . Vascular endothelial growth factor has also been associated with liver metastasis and poorer survival time (23 -25) and may confer a survival advantage to tumor cells by up-regulating the antiapoptotic protein Bcl-2 (26, 27) . However, the prognostic value of this protein has not yet been fully established.
Apoptosis protease activating factor-1 (APAF-1) is a novel tumor marker recently investigated in CRC for its potential prognostic value. In mismatch repair -proficient tumors, loss of APAF-1 was significantly linked with more advanced T and N stage as well as poor survival (28) . The metastatic potential of the Raf-1 kinase inhibitor protein (RKIP), a known critical down-regulator of the mitogen-activated protein kinase signaling pathway, has been shown in several tumor types (29 -31) . Loss of RKIP was also found to be associated with N stage, the presence of vascular invasion and metastasis in mismatch repair -proficient CRC, and worse survival time (28, 32) .
The aim of this study was to identify clinicopathologic features, tumor markers, or combinations of these, leading to the identification of patients with mismatch repair -proficient CRC at high risk of developing metastasis and, consequently, more likely to benefit from adjuvant therapy. Using a tissue microarray, a comprehensive panel of 22 tumor markers and several well-established clinicopathologic features were analyzed on 387 CRC patients with known metastatic status. Independent predictive factors were identified and validated on a separate cohort of 810 patients with complete clinicopathologic data including 10-year follow-up. The protein markers selected for this study represent (a) novel and promising prognostic factors (APAF-1, RKIP, MST1, EphB2, CD44, MUC1, MUC2, tumor-infiltrating lymphocytes, and RHAMM); (b) known mediators of cell cycle arrest, proliferation, and apoptosis (Bcl-2, Ki-67, p21, p27, and p53); and (c) proteins involved in signaling pathways leading to tumor progression and metastasis, which include the Wnt (adenomatous polyposis coli, h-catenin, and E-cadherin), transforming growth factor-h (phosphor-SMAD2), Ras/mitogen-activated protein kinase, and phosphatidylinositol 3-kinase/AKT (phosphoextracellular signal -regulated kinase, epidermal growth factor receptor, and phospho-AKT) signaling pathways.
Materials and Methods
Tissue microarray construction. A tissue microarray of 1,420 unselected, nonconsecutive primary CRCs was constructed (33) . Briefly, formalin-fixed, paraffin-embedded tissue blocks of CRC resections were obtained. One tissue cylinder with a diameter of 0.6 mm was punched from morphologically representative tissue areas of each donor tissue block and brought into one recipient paraffin block (3 Â 2.5 cm) using a home-made semiautomated tissue arrayer.
Immunohistochemistry. 30 min at room temperature. For visualization of the antigen, the sections were immersed in 3-amino-9-ethylcarbazole+substrate-chromogen (DakoCytomation) for 30 min and counterstained with Gill's hematoxylin. Immunohistochemistry was done similarly for a panel of 22 markers as outlined in Table 1 . In addition, CD8 was used as a marker for intraepithelial tumor-infiltrating lymphocytes. Evaluation of immunohistochemistry. Immunoreactivity was assessed for each protein in a semiquantitative manner by scoring the proportion of positive tumor cells over the total number of tumor cells ranging from 0% to 100% using 5% increments (0%, 5%, 10%, etc.). The reproducibility of this scoring method between multiple pathologists has previously been assessed (22, 28, 34) . Staining intensity was not assessed. MLH1, MSH2, and MSH6 were scored as negative (0% staining) or positive (>0% staining).
DNA mismatch repair status. The 1,420 CRCs were stratified according to DNA mismatch repair status and consisted of 1,197 mismatch repair -proficient tumors expressing MLH1, MSH2, and MSH6; 141 MLH1-negative tumors; and 82 presumed Lynch syndrome/ hereditary nonpolyposis colorectal cancer cases showing loss of MSH2 and/or MSH6 at any age or loss of MLH1 at <55 years (35) . Only mismatch repair -proficient cases were included in this study to ensure a homogeneous sample of CRCs.
Clinicopathologic data of mismatch repair -proficient CRCs. The clinicopathologic data for the 1,197 mismatch repair -proficient CRC patients included T stage, N stage, tumor grade, vascular invasion, and 10-year survival. Peritumoral lymphocyte invasion at the invasive front and tumor budding were evaluated using the original H&E slides of the resection specimens corresponding to each tissue microarray punch. The clinicopathologic features for patients with mismatch repairproficient CRC are summarized in Table 2 .
In addition to these features, M stage and treatment information was available for 387 CRCs. This subgroup of mismatch repair -proficient tumors was used as a test set to identify patients at high risk of metastasis. It included 74 (19.1%) patients with metastasis to the liver (stage IV disease; ref. 36) , 54 (15.3%) with stage I tumors (T 1 or T 2 , N 0 , M 0 ), 112 (31.6%) with stage II (T 3 or T 4 , N 0 , M 0 ), and 119 (33.6%) with stage III (any T, >N 0 , M 0 ). Most patients (n = 286) were treated with surgery alone whereas 88 also received adjuvant therapy.
Selecting cutoff scores for protein positivity/overexpression. A cutoff score for positive immunohistochemistry expression or overexpression for each of the 22 proteins was determined using receiver operating characteristic curve analysis (37) . Briefly, the sensitivity and 1-specificity for discriminating presence and absence of metastasis was determined at each percentage score and plotted, thus generating a receiver operating characteristic curve. The (0, 1) criterion was used to select the score minimizing the trade-off between sensitivity and specificity, thus leading to the greatest number of tumors correctly classified as having metastasis or not. In addition, 100 bootstrapped replications were done to resample the data and determine the reliability of the cutoff scores for each protein.
Statistical analysis. The association of clinicopathologic features and protein expression with the presence of metastasis was evaluated using univariate logistic regression analysis on the first group of 387 mismatch repair -proficient CRC patients for whom M stage was known. P values, odds ratios (OR), and 95% confidence intervals (95% CI) were used to determine the effect of each variable on metastasis. All variables significantly associated (P < 0.05) with metastasis were entered into a multivariate logistic regression model. A forward selection procedure was used to identify independent predictors of metastasis. The probability of developing metastasis with each combination of predictors was obtained from the logistic regression equation (38) . One hundred -fold cross-validation was done to determine the sensitivity and specificity of the final model. The 
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combination of independent predictive factors was then validated on the remaining mismatch repair -proficient CRCs (n = 810) by survival analysis. The Kaplan-Meier method and the log-rank test were used in univariate survival analysis. The independent effect of each variable in multivariate analysis was determined by Cox proportional hazards regression and hazard ratios (HR) and 95% CIs were obtained. Due to the multiplicativity of HRs, the relative risk of death for each combination of features in the validation group was determined. The sensitivity and specificity of every combination for death from CRC were determined. All analyses were carried out using SAS version 9.1 (SAS Institute).
Results
Association of clinicopathologic features with metastasis. 
months).
Association of protein expression with metastasis. Of the 22 tumor markers analyzed, only positive expression of nuclear h-catenin (P = 0.015), overexpression of cytoplasmic RHAMM (P = 0.008), negative expression of cytoplasmic RKIP (P = 0.001), and absence of intraepithelial lymphocytes (P = 0.017) were significantly associated with the presence of metastasis (Table 3) .
Multivariate analysis of metastasis. Of the 10 clinicopathologic features and proteins entered into multivariate analysis, N stage [P < 0.001; OR, 9.43 (95% CI, 3.6-24.9)], vascular invasion [P = 0.009; OR, 2.83 (95% CI, 1.3-6.2)], and RKIP expression [P = 0.003; OR, 0.28 (95% CI, 0.12-0.65)] were found to independently predict metastasis (Table 4) . Nodepositive patients with vascular invasion and negative RKIP expression had the greatest probability of developing metastasis (probability = 0.75) whereas node-negative patients without vascular invasion and with positive RKIP expression had only a probability of 0.03. Interestingly, a subgroup of node-negative patients, which included T 2 to T 4 tumors, showed a nearly identical probability of metastatic risk (24%) with nodepositive patients with no vascular invasion and positive RKIP expression (22%). The cross-validated sensitivity and specificity of the final model were 93% and 58%, respectively. Table 5 . A comparison of the survival times with metastatic risk in Table 3 reveals several similarities between the two independent groups of patients. The longest survival time (107.0 months) corresponds to the combination N 0 /absence of invasion/positive RKIP, which was also found to have the lowest probability of metastatic risk and served as a baseline hazard (HR, 1.0). Patients with positive lymph nodes, presence of invasion, and negative RKIP were most likely to develop metastatic disease and also showed the worse survival (19.0 months). Moreover, their relative risk of death was determined to be 6.87 times greater than that for patients with N 0 disease, with absence of vascular invasion and positive RKIP expression. All patients with these characteristics died of CRC within the first 58 months after diagnosis. Patients with the combination N 0 /presence of invasion and negative RKIP and patients with >N 0 /absence of invasion and positive RKIP not only had similar survival times (45.0 and 47.0 months, respectively) and relative risk of death (HR, 2.79 and 2.46, respectively) but were additionally found to have nearly identical probabilities of developing metastatic disease (0.24 and 0.22, respectively). Furthermore, patients with the most adverse combination of features and those with metastatic disease had comparable survival times (P = 0.997; Fig. 1 ).
Discussion
Adjuvant chemotherapy/radiotherapy can improve prognosis in patients with resected CRC. Several studies have described overall 5-year survival rates approaching 20 months and response rates of nearly 50% with certain drug combinations (39) . The most important prognostic factor and indicator of possible micrometastatic disease is tumor stage (TNM) at the time of surgery (1, 2) . Although adjuvant therapy is considered standard care for patients with stage III disease, it is not routinely recommended for patients with stage II disease (2, 9) . Unfortunately, 25% to 35% of these patients with pN 0 cancers develop extranodular metastases within the first 5 years (40, 41) .
The present study was undertaken to identify independent clinicopathologic factors and tumor markers leading to the identification of patients at risk of developing metastasis and, consequently, more likely to benefit from adjuvant therapy.
In multivariate analysis, the combination of N stage, vascular invasion, and RKIP expression provided independent predictive information on metastatic disease. In general, patients with lymph node involvement were more likely to develop metastasis than patients with N 0 tumors regardless of vascular invasion and RKIP expression. Patients at highest risk of developing metastasis had lymph node involvement, vascular invasion, and negative immunohistochemical expression of RKIP, whereas the opposite features conferred a risk of only 3%. Interestingly, a subgroup of patients with N 0 tumors showed a similar clinical outcome as node-positive disease. The sensitivity of the combined analysis of N stage, vascular invasion, and RKIP expression was high (93%), suggesting a strong predictive potential for this model.
To validate our findings, a second group of CRCs was included in the study. Patients were stratified according to N stage, vascular invasion, and RKIP expression. The 10-year disease-specific survival time was analyzed for each combination of features. Patients with the most adverse combination, and therefore with the highest risk of metastasis, also had the worst survival (19.0 months), whereas patients with the least amount of risk based on the predictive model (no lymph node involvement, absence of vascular invasion, and positive RKIP expression) showed a significantly longer survival time (107.0 months).
Not only was the risk of metastatic disease in patients with node-positive tumors with absence of invasion and positive RKIP expression (22%) nearly identical with that in patients with node-negative tumors with invasion and negative RKIP expression (24%) but also the survival times of both were strikingly similar (47.0 and 45.0, respectively).
The survival times of each combination of N stage, vascular invasion, and RKIP expression reflected metastatic risk in all but one occasion (i.e., in node-negative patients with vascular invasion and positive RKIP expression). The ORs and HRs for metastasis and survival time, respectively, show that RKIP expression has a significantly greater effect on predicting metastasis than vascular invasion whereas the opposite is found for survival time. The role of RKIP as a predictive marker of metastasis, rather than an independent prognostic factor, is highlighted by these results.
Several studies have identified the protein RKIP as a suppressor of metastasis (30 -32, 42, 43) . Loss of RKIP expression is associated with metastatic progression in breast cancer, prostate cancer, CRC, and melanoma, as well as with resistance to chemotherapy (30 -32, 42 -44) . Our results have identified RKIP as the only independent predictive marker of metastasis among 21 other tumor markers studied by immunohistochemistry. The susceptibility of RKIP-negative tumors to chemotherapy has not yet been evaluated in CRC. The majority of the CRCs at higher metastatic risk in this study were indeed negative for the protein. Therefore, response of these patients to chemotherapy merits further investigation.
Several markers included in the analysis have previously been shown to have an effect on prognosis in patients with CRC, such as epidermal growth factor receptor. Sources contributing to discrepant findings from different prognostic studies include methodologic differences; poor study design; nonstandardized assays, which lack reproducibility; and inappropriate or misleading statistical analyses often done on underpowered patient samples (45) . The recent REMARK recommendations for reporting of tumor markers in prognostic studies should help reduce these inconsistencies (45) . In addition, a wide range of scoring methods used to evaluate immunoreactivity as well as the use of predetermined and often unvalidated or unjustified cutoff scores for tumor marker ''positivity'' is a major cause of the conflicting findings reported in the literature on the same tumor marker (46, 47) .
In this study, we combined tissue microarray technology on >1,000 patients, a system made even more powerful by the use of a reproducible semiquantitative scoring method. Moreover, receiver operating characteristic curve analysis was used to select the most sensitive and specific cutoff scores for tumor marker positivity, with the presence or absence of metastasis as the end point, and validated by resampling of the data.
In conclusion, the combined analysis of N stage, vascular invasion, and RKIP expression is highly predictive of metastasis in patients with mismatch repair -proficient CRC. Additionally, these results suggest that a subgroup of more aggressive N 0 tumors can be recognized by evaluating the presence of vascular invasion and expression of RKIP, thereby identifying stage II cancers that should be considered for radiotherapy or combined modality therapy.
